Immatics (NASDAQ:IMTX) Given New $23.00 Price Target at Mizuho

Immatics (NASDAQ:IMTX) had its price objective increased by equities researchers at Mizuho from $19.00 to $23.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 125.05% from the stock’s current price.

IMTX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a research report on Wednesday, October 8th. Guggenheim boosted their price objective on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Zacks Research upgraded Immatics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

Immatics Price Performance

Shares of IMTX opened at $10.22 on Wednesday. The stock has a market capitalization of $1.24 billion, a PE ratio of -10.04 and a beta of 1.24. The business’s fifty day moving average price is $8.97 and its 200 day moving average price is $6.85. Immatics has a 12-month low of $3.30 and a 12-month high of $11.25.

Institutional Trading of Immatics

A number of large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after acquiring an additional 2,231 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in shares of Immatics in the second quarter worth about $59,000. Insigneo Advisory Services LLC purchased a new position in shares of Immatics in the third quarter worth approximately $103,000. Engineers Gate Manager LP purchased a new stake in shares of Immatics in the 2nd quarter valued at approximately $124,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Immatics in the second quarter valued at $136,000. 64.41% of the stock is currently owned by institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.